Evaluation of Mangosteen juice blend on biomarkers of inflammation in obese subjects: a pilot, dose finding study
Evaluation of Mangosteen juice blend on biomarkers of inflammation in obese subjects: a pilot, dose finding study
复制标题
DOI：
10.1186/1475-2891-8-48
复制
发表时间：
2009-10-20
影响因子：
5.4
通讯作者：
Singh, Vijay J.
中科院分区：
文献类型：
--
作者：
Udani, Jay K.;Singh, Betsy B.;Singh, Vijay J.
背景：在超重和肥胖个体中减少炎症的能力在防止进展为代谢综合征以及心脏病和糖尿病的相关风险方面可能是有价值的。这项研究的目的是评价多剂量山竹果果汁混合物对C反应蛋白(CRP)水平升高的肥胖症患者炎症指标和抗氧化水平的影响。方法：该研究是一项为期8周的随机、双盲、安慰剂对照研究，研究前2周为冲洗期。这项研究包括四组，包括安慰剂和三种不同剂量的测试产品XanGo Juice(TM)：每天两次，每次3、6或9盎司。这项研究的主要结果衡量标准是高敏感性(HS)-CRP。次要结果指标包括炎症的其他生化指标、拟人化指标和安全性评估。结果：122人进入研究，44人随机，40人完成研究。治疗8周后，所有3个剂量组的Hs-CRP测定值均较基线有所下降，而安慰剂组则有所上升。与基线相比，这些变化并不显著，但与安慰剂相比，18盎司组与基线相比变化显著(p=0.02)。与安慰剂相比，其他炎症标志物(炎性细胞因子)和脂质过氧化标志物(F2异前列腺素)没有显示出任何显著差异。果汁组的BMI有下降的趋势。在任何一组中都没有报告副作用，实验室或EKG安全性评估也没有显示任何受试者的临床显著变化。结论：在这项试点的剂量发现研究中，与每天服用最高剂量18盎司的安慰剂相比，专利山竹果汁混合物(XanGo Juice T)降低了CRP水平(与基线相比变化更大)。需要对更多的人群进行进一步的研究，以确认和进一步确定这种果汁的好处。这种果汁是安全服用的。
Background: The ability to reduce inflammation in overweight and obese individuals may be valuable in preventing the progression to metabolic syndrome with associated risks for heart disease and diabetes. The purpose of this study was to evaluate the effect of multiple dosages of a proprietary Mangosteen Juice blend on indicators of inflammation and antioxidant levels in obese patients with elevated C-reactive protein (CRP) levels.Methods: The study was an 8 week randomized, double-blind, placebo-controlled study with a pre-study 2 week washout period. The study included four groups including placebo and three difference doses of the test product, XanGo Juice (TM): 3, 6 or 9 oz twice daily. The primary outcome measure of this study was high-sensitivity (HS)-CRP. Secondary outcome measures included other biochemical indicators of inflammation, anthropomorphic measures and a safety evaluation.Results: One hundred twenty two (122) persons were screened for the study, 44 were randomized and 40 completed the study. HS-CRP measurements dropped after 8 weeks treatment compared to baseline in all 3 dose groups and increased in the placebo group. The changes from baseline were not significant but the comparison of change from baseline was significant for the 18 oz group when compared to placebo (p = 0.02). Other markers of inflammation (inflammatory cytokines) and a marker for lipid peroxidation (F2 isoprostane) did not show any significant differences when compared with placebo. There was a trend towards a decrease in BMI in the juice groups. There were no side effects reported in any of the groups and none of the laboratory or EKG safety assessments indicated clinically significant changes for any subject.Conclusion: In this pilot, dose-finding study, a proprietary mangosteen juice blend (XanGo Juice T) reduced CRP levels (increased change from baseline) compared to placebo for those taking the highest dose of 18 oz per day. Further studies with a larger population are required to confirm and further define the benefits of this juice. The juice was administered safely.